Posttransplant maintenance therapy in multiple myeloma: the changing landscape

@inproceedings{Sengsayadeth2017PosttransplantMT,
  title={Posttransplant maintenance therapy in multiple myeloma: the changing landscape},
  author={Salyka M Sengsayadeth and Florent Malard and Bipin N Savani and Laurent Garderet and Mohamad Mohty},
  booktitle={Blood cancer journal},
  year={2017}
}
Transplant-eligible patients with multiple myeloma (MM) now have extended survival after diagnosis owing to effective modern treatment strategies that include new agents in induction therapy, autologous stem cell transplant (ASCT), consolidation therapy and posttransplant maintenance therapy. Standard of care for newly diagnosed, fit patients includes ASCT and, often nowadays, posttransplant maintenance. Several large studies have shown the efficacy of maintenance with thalidomide, lenalidomide… CONTINUE READING
Highly Cited
This paper has 243 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 26 times over the past 90 days. VIEW TWEETS
5 Citations
78 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 78 references

An openlabel, randomised phase 3 study of daratumumab, lenalidomide, and dexamethasone (DRD) versus lenalidomide and dexamethasone (RD) in relapsed or refractory multiple myeloma (RRMM): POLLUX

  • M Dimopoulos, A Oriol, N Nahi, J San Miguel, N Bahlis, N Rabin
  • Haematologica
  • 2016

Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): a metaanalysis (MA) of overall survival (OS)

  • M Attal, A Palumbo, SA Holstein, V Lauwers-Cances, MT Petrucci, PG Richardson
  • ASCO Meeting Abstr 2016;
  • 2016

Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial)

  • M Cavo, A Palumbo, S Zweegman, MA Dimopoulos, R Hajek, L Pantani
  • ASCO Meeting Abstr 2016;
  • 2016

Weekly carfilzomib, cyclophosphamide and dexamethasone (WKCYD) followed by maintenance with weekly carfilzomib (WK) in elderly patients with newly diagnosed multiple myeloma (NDMM)

  • S Bringhen, L De Paoli, A Larocca, S Ballanti, F Gentilini, AM Liberati
  • Haematologica
  • 2016

Autologous transplantation for multiple myeloma in the era of new drugs : a phase III study of the Intergroupe Francophone Du Myelome ( IFM / DFCI 2009 trial )

  • M Attal, V Lauwers-Cances, C Hulin, T Facon, D Caillot, M Escoffre
  • Blood
  • 2015

Bortezomib induction and maintenance in patients with newly diagnosed multiple myeloma: long-term follow-up of the HOVON-65/GMMG-HD4 Trial

  • P Sonneveld, H-J Salwender, B Van Der Holt, L el Jarari, U Bertsch, IW Blau
  • Blood
  • 2015

Similar Papers

Loading similar papers…